BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC) (BELIEF)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT01562028 |
|
Recruitment Status :
Completed
First Posted : March 23, 2012
Results First Posted : October 31, 2019
Last Update Posted : October 31, 2019
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Rationale:
Advanced non-small-cell lung cancer (NSCLC) patients harbouring epidermal growth factor receptor (EGFR) mutations (del19 or L858R) show an impressive progression-free survival between 9 and 14 months when treated with erlotinib. However, the presence of EGFR mutations can only imperfectly predict outcome. The investigators hypothesize that progression-free survival could be influenced both by the pretreatment EGFR T790M mutation and by components of DNA repair pathways.
The investigators propose a model of treatment whereby patients with EGFR mutations (single or with T790M) can attain a benefit with longer overall PFS when treated with erlotinib plus bevacizumab. When the patients are grouped by BRCA1 mRNA levels and T790M the hypothesis is that the combination of erlotinib plus bevacizumab can improve the PFS in all subgroups.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Lung Cancer | Drug: Erlotinib Drug: Bevacizumab | Phase 2 |
Objectives:
- To determine long-term outcome of patients with advanced non-squamous NSCLC harbouring EGFR mutations with or without T790M mutation at diagnosis and treated with the combination of erlotinib and bevacizumab. Primary endpoint: progression-free survival
- To evaluate the efficacy and tolerability of the combination
- To evaluate the correlation of BRCA1 mRNA and AEG-1 mRNA expression and T790M with progression-free survival
- To monitor EGFR mutations (including T790M) in serum and plasma longitudinally
- To evaluate molecular biomarkers related to EGFR TKI and bevacizumab
Design:
This is a multinational, multi-center phase II trial of erlotinib plus bevacizumab in patients with advanced non-squamous NSCLC harbouring EGFR mutations confirmed by central re-assessment. Patients will be stratified into two subgroups, with and without EGFR T790M mutation. The stratification will be done after the inclusion of patients.
Sample size: 102 patients
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 109 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | An Open-label Phase II Trial of Erlotinib and Bevacizumab in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations |
| Study Start Date : | June 2012 |
| Actual Primary Completion Date : | October 31, 2018 |
| Actual Study Completion Date : | October 31, 2018 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Erlotinib plus bevacizumab
Patients will be treated with erlotinib and bevacizumab. Bevacizumab: 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days) Erlotinib: 150 mg p.o., daily
|
Drug: Erlotinib
Patients will be treated with erlotinib, 150 mg p.o., daily
Other Name: Tarceva (R) (Roche) Drug: Bevacizumab Patients will be treated with bevacizumab 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days)
Other Name: Avastin (R) Roche) |
- Progression Free Survival [ Time Frame: From the date of enrollment until documented progression or death, whichever occurs first, assessed up to 48 months. ]
Time from the date of enrollment until an investigator-documented progression or death, whichever occurs first.
Assessment of Progressive Disease (PD) is based on Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1): at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum recorded on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
- Overall Survival [ Time Frame: From the date of enrollment until death, assessed up to 48 months. ]Time from the date of enrollment until death from any cause.
- Time to Treatment Failure [ Time Frame: From the date of enrollment until discontinuation of treatment, assessed up to 48 months. ]Time from the date of enrollment to discontinuation of treatment for any reason including progression of disease (based on RECIST v1.1), treatment toxicity (adverse events classified according to NCI CTCAE version 4.), refusal and death.
- Objective Response [ Time Frame: Assessed across all time-points from enrollment to termination of trial treatment (max 48 months). ]
Objective response is defined as best overall response (CR or PR) across all assessment time-points during the period from enrollment to termination of trial treatment. Objective response, along with progressive and stable disease, will be determined using RECIST 1.1 criteria:
Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.
Progression (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum recorded on the trial. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum of diameters recorded on the trial.
- Disease Control [ Time Frame: Assessed across all time-points from enrollment to termination of trial treatment (max 48 months). ]
Disease control is defined as achieving objective response (CR or PR, across all time-points from enrollment to termination of trial treatment) or stable disease for at least 6 weeks. Objective response, along with SD (disease control) and PD (no disease control), will be determined using RECIST 1.1 criteria:
Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.Progression (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum recorded on the trial. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum of diameters recorded on the trial.
- Duration of Response [ Time Frame: Assessed across all time-points from enrollment to to the date of first documented progression or relapse (max 48 months). ]
Interval from the date of first documentation of objective response (CR or PR) to the date of first documented progression or relapse. Assessment of Objective response and Progressive Disease (PD) is based on the RECIST 1.1 criteria:
Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions taking as reference the baseline sum of diameters.
Progression (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum recorded on the trial. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm.
Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum of diameters recorded on the trial.
- Adverse Events [ Time Frame: Assessed across all time-points until end of treatment (30 +/-5 days following the last dose of study drug) (max 48 months). ]Adverse events graded according to NCI CTCAE V4.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age ≥ 18 years
- ECOG performance status 0-2
- Adequate haematological function, coagulation, liver function and renal function
- Pathological diagnosis of predominantly non-squamous, non-small-cell lung cancer (NSCLC)
- TNM version 7 stage IV disease including M1a (malignant effusion) or M1b (distant metastasis), or locally advanced disease not amenable to curative treatment (including patients progressing after radiochemotherapy for stage III disease)
- Measurable or evaluable disease (according to RECIST 1.1 criteria).
- Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R)
Exclusion Criteria:
- Patients with increased risk of bleeding
- Patients with clinically significant cardiovascular diseases
- Patients with a history of thrombosis or thromboembolism in the 6 months prior to treatment
- Patients with gastrointestinal problems
- Patients with neurologic problems
- Patients who have had in the past 5 years any previous or concomitant malignancy EXCEPT adequately treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, in situ breast carcinoma.
- Patients with any known significant ophthalmologic anomaly of the ocular surface
- Patients who received prior chemotherapy for metastatic disease
- Patients who received previous treatment for lung cancer with drugs targeting EGFR or VEGF
- Pregnancy
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01562028
Show 48 study locations
| Study Chair: | Rafael Rosell, MD | Catalan Institute of Oncology, Hospital Germans Trias i Pujol | |
| Study Chair: | Stahel Rolf, MD | Laboratory of Molecular Oncology, Clinic of Oncology, University Hospital Zuerich | |
| Study Chair: | Miquel Taron | Medical Oncology Service-ICO, Hospital Germans Trias i Pujol |
Documents provided by European Thoracic Oncology Platform:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | European Thoracic Oncology Platform |
| ClinicalTrials.gov Identifier: | NCT01562028 |
| Other Study ID Numbers: |
ETOP 2-11 / MO27911 2011-004481-15 ( EudraCT Number ) MO27911 ( Other Identifier: Roche ) |
| First Posted: | March 23, 2012 Key Record Dates |
| Results First Posted: | October 31, 2019 |
| Last Update Posted: | October 31, 2019 |
| Last Verified: | October 2019 |
|
non small cell lung cancer advanced non-squamous EGFR mutations |
|
Lung Neoplasms Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site Neoplasms Lung Diseases Respiratory Tract Diseases Bevacizumab Erlotinib Hydrochloride Antineoplastic Agents, Immunological |
Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Protein Kinase Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |